SARS-CoV-2 infection
Conditions
Interventions
Group 1 :Molnupiravir
Group 2:No
Sponsors
The First Affiliated Hospital of Naval Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Voluntarily sign the informed consent; 2. Gender is not limited, at least 18 years old, and < 60 years old; 3. Within 5 days before screening, with or without pneumonia-related symptoms, confirmed SARS-CoV-2 infection by PCR test; 4. Able to swallow capsule medicine; 5. Agree not to participate in other interventional clinical trials for the treatment of SARS-CoV-2 during the study period; 6. Agree not to take other investigational drugs except monaprevir; 7. Comply with research requirements.
Exclusion criteria
Exclusion criteria: 1. Novel coronavirus positive patients; 2. Patients infected with novel coronavirus (2019-nCoV) (severe or critical illness); 3. Had a history of severe allergic reactions, including generalized urticaria, angioedema, and hypersensitivity reactions; 4. Have received COVID-19 convalescent plasma, SARS-CoV-2 antibody treatment; 5. Have received other investigational drugs for the treatment of SARS-CoV-2; 6. Pregnant or lactating women; 7. The researchers judged that they are not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Virus negative rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| The viral RNA negative rate in nasopharyngeal swabs;The change of viral RNA in nasopharyngeal swabs;Hospital discharge rate;Clinical outcome; | — |
Countries
China
Contacts
Public ContactLiang Xuesong
Department of Infectious Diseases, Changhai Hospital Affiliated to Naval Military Medical University
Outcome results
None listed